Skip to main content
DutyStation
Search
📰 GeneralCNBCFriday, October 2, 2026 at 3:20 PM UTC1h ago

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes

Read full article at CNBC →

Originally published by CNBC. Summary and curation by DutyStation News.

📰 Related Stories

Dots get up in Muse’s business
📰 General

Dots get up in Muse’s business

The Verge36m ago
📰 General

Pope Leo XIV is not a fan of AI-generated art

TechCrunch43m ago
📰 General

The sector in the cross hairs of the bond sell-off looks poised for a bounce, says Mike Khouw

CNBC49m ago
📰 General

Laytr’s new app lets you save anything you find online, not just articles to read

TechCrunch52m ago
Nothing will let you test new products early with its ‘Community Review’ program
📰 General

Nothing will let you test new products early with its ‘Community Review’ program

9to5Google53m ago
📰 General

American starts letting customers mix cash and miles for tickets

CNBC1h ago
← Back to News